News | Antiplatelet and Anticoagulation Therapies | September 25, 2015

Mount Sinai Heart Trial Re-examines DAPT for Coronary Stent Patients

International study will assess safety, effectiveness of aspirin plus ticagrelor versus ticagrelor alone

September 25, 2015 – The Icahn School of Medicine at Mount Sinai has launched the international TWILIGHT clinical trial to test the safety and effectiveness of treating coronary stent patients with ticagrelor alone instead of combining it with aspirin, which is the current standard of care. Researchers will analyze the potential benefits of administering ticagrelor to reduce clotting while at the same time reducing the risk of bleeding associated with the use of both medications. 

"This global study will re-examine the traditional use of dual antiplatelet therapy after coronary artery stenting, and determine whether aspirin can be safely withdrawn,” said TWILIGHT’s Global Principal Investigator Roxana Mehran, M.D., director of the Office of Interventional Cardiovascular Research and Clinical Trials of Mount Sinai Heart and professor of cardiology and population health science and policy at Icahn School of Medicine at Mount Sinai. “Our research team will determine the effectiveness and safety of ticagrelor alone, compared to using ticagrelor plus aspirin, to reduce the occurrence of bleeding and adverse events after cardiac stenting.”

“This clinical trial will test the feasibility of withdrawing aspirin in high-risk patients undergoing percutaneous coronary intervention (PCI) with drug-eluting stents,” said Samin K. Sharma, M.D., director of clinical and interventional cardiology for the Mount Sinai Health System. “Mount Sinai Heart looks forward to conducting this exciting, large-scale investigation to help improve PCI patient care around the world.”

For patients receiving a cardiac stent in a cardiac catheterization laboratory through a minimally invasive PCI procedure, current medical guidelines advise that patients receive dual antiplatelet therapy (DAPT) with both aspirin and a drug from a class of stronger antiplatelet medications called P2Y12 inhibitors (e.g. ticagrelor). Such medications prevent blood clots that can lead to heart attack or stroke by reducing the ability of platelets to stick to one another and form a clot.

“This innovative clinical trial will provide novel insights on an antiplatelet strategy in high-risk patients that we hypothesize will simultaneously reduce bleeding while maintaining anti-ischemic efficacy, thereby improving net clinical benefit over current standard of care,” said Usman Baber, M.D., MS, chair of the TWILIGHT Clinical Coordinating Center and director of clinical biometrics at the Office of Interventional Cardiovascular Research and Clinical Trials at Mount Sinai.

The trial will enroll up to 9,000 study subjects at 100 sites across the United States, Canada, Europe, South America and Asia. After three months of being prescribed DAPT, patients will be blindly randomized to start receiving either ticagrelor (90mg) plus aspirin (81mg daily) for 12 months, or ticagrelor plus placebo. Researchers will track the occurrence of any clinically relevant bleeding, or adverse events such as mortality, heart attack and stroke.

Patients eligible to enroll in the clinical trial are those high-risk patients 18 years of age or older who have undergone successful PCI with at least one drug-eluting stent and discharged on DAPT with aspirin and ticagrelor for a three-month duration.

Ticagrelor is made by AstraZeneca, which is providing funding support for the study. Mehran  receives financial compensation as a consultant and advisory board member for AstraZeneca.

For more information: www.mountsinaihealth.org

Related Content

Shockwave Launches Coronary Intravascular Lithotripsy in Europe
News | Cath Lab | May 30, 2018
Shockwave Medical recently announced the European commercial availability of Intravascular Lithotripsy (IVL) for...
FFR software on the GE Centricity CVIS. A trial from the 2018 EuroPCR meeting showed FFR improves long-term outcomes.
News | Cath Lab | May 29, 2018
May 29, 2018 — Ongoing controversy exists regarding the role of percutaneous coronary intervention (PCI) for stable c
SCAI Updates Consensus on Length of Stay for Percutaneous Coronary Intervention
News | Cath Lab | May 15, 2018
Revised guidelines incorporating new data on discharge criteria for patients undergoing elective percutaneous coronary...
No Benefit Found Using Sodium Bicarbonate, Acetylcysteine to Prevent Kidney Injury, the result of the PRESERVE Trial to prevent acute kidney injury (AKI), presented at SCAI 2018.  #SCAI, #SCAI2018,
Feature | Cath Lab | May 15, 2018
May 15, 2018 – The large-scale, international randomized PRESERVE clinical trial found high-risk patients for renal c
Angiogram of a STEMI patient.
News | Cath Lab | May 15, 2018
May 15, 2018 — A contemporary, real-world analysis shows lower mortality rates when culprit-only intervention is used
Recent Acquisitions Eroding Prices in Billion Dollar European Interventional Cardiology cath lab Market.
Feature | Cath Lab | May 07, 2018 | Simon Trinh and Jeffrey Wong
The European interventional cardiology market is currently valued at nearly $1.4 billion.
Videos | Cath Lab | May 07, 2018
Imran Ahmad, M.D., medical director of interventional cardiology, explains some of the new technologies his labs have
360 Photos | Cath Lab | April 20, 2018
A 360 degree view of the newest cath lab at Northwestern Medicine Central DuPage Hospital in Winfield, Ill., located
SCAI Announces Global Lecture Series for 2018 Scientific Sessions
News | Cath Lab | April 18, 2018
Many of the world’s leading interventional cardiologists and cardiovascular professionals will convene in San Diego,...
Serial coronary angiograms of the representative case treated with shockwave intravascular lithotripsy.

Figure 1. Serial coronary angiograms of the representative case treated with shockwave intravascular lithotripsy.

Feature | Cath Lab | April 16, 2018 | Azeem Latib, M.D.
Over the last decade, there have been considerable developments in procedural techniques and technology facilitating
Overlay Init